AAPL 171.24 +2.63 (+1.56%)MSFT 110.63 +1.88 (+1.73%)FB 146.64 +4.56 (+3.21%)ZNGA 3.8 +0.15 (+3.97%)NVDA 152.46 +4.29 (+2.89%)WBA 83.03 +1.21 (+1.48%)GOOG 1080.15 +28.57 (+2.72%)PIH 5 -0.12 (-2.34%)
AAPL 171.24 +2.63 (+1.56%)MSFT 110.63 +1.88 (+1.73%)FB 146.64 +4.56 (+3.21%)ZNGA 3.8 +0.15 (+3.97%)NVDA 152.46 +4.29 (+2.89%)WBA 83.03 +1.21 (+1.48%)GOOG 1080.15 +28.57 (+2.72%)PIH 5 -0.12 (-2.34%)

Cash Flow ABIO Quote ARCA biopha

All | Income Statement | Balance Sheet | Cash Flow | Retained Earnings | PPE Schedule | Intangible and Goodwill Schedule
Year 201420152016
NetIncome -10 -11 -16
Depreciation 0 0 0
DeferredIncomeT 0 0 0
StockBasedCompe 1 1 1
AccountsReceiva 0 0 0
InventoryCS 0 0 0
AccountsPayable 0 0 1
OtherWorkingCap 0 0 0
OtherNonCashIte 0 0 0
NetCashProvided -9 -11 -15
InvestmentsInPP 0 0 0
AcquisitionsNet 0 0 0
PurchasesOfInve 0 0 -21
SalesMaturities 0 0 4
PurchasesOfInta 0 0 0
OtherInvestingA 0 0 0
NetCashUsedForI 0 0 -16
DebtIssued 0 0 0
DebtRepayment 0 0 0
CommonStockIssu 9 37 0
CommonStockRepu 0 0 0
DividendPaid 0 0 0
OtherFinancingA -1 -3 0
NetCashProvided 8 34 0
NetChangeInCash -1 23 -31
CashAtBeginning 17 15 39
CashAtEndOfPeri 15 39 7
ARCA biopharma Inc. income statement is the only one that provides an overview of company sales and net income
The reasoning behind the adjustment, however, is that free cash flow is meant to measure money being spent right now, not transactions that happened in the past. This makes ARCA biopharma Inc. FCF a useful instrument for identifying growing companies with high up-front costs, which may eat into earnings now but have the potential to pay off later.